Clinical trials in the UK to prove the effectiveness of PBM (photobiomodulation therapy) – otherwise known as low-level laser therapy – looks set to increase. Last year NICE (National Institute for Health and Care Excellence) approved low-level laser for oral mucositis (OM) – one of the common side effects caused by radiotherapy and chemotherapy for cancer patients. Clinicians at Southampton University Hospital carried out clinical trials to show the effectiveness of using low-level laser to prevent OM, and / or to treat its symptoms which include inflammation and pain. NICE has subsequently approved low-level laser as a safe and effective treatment.
Low-level laser is used to treat many inflammatory conditions and is effective in management of acute and chronic pain. In America the FDA has approved low-level laser for many conditions, and I hope to see NICE do the same.